Holen Sie sich die Stockscreener-App
27.74
5.88%
1.54
Vorhandelsmarkt:
28.00
0.26
+0.94%
Schlusskurs vom Vortag:
$26.20
Offen:
$26.32
24-Stunden-Volumen:
45,762
Relative Volume:
3.68
Marktkapitalisierung:
$259.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.52%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$25.00
$28.16
1-Wochen-Bereich:
$25.00
$28.16
52-Wochen-Spanne:
$15.80
$28.55
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
27.74 | 259.67M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent
BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq
TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com
Shareholders sue to block Stamford-based Cara Therapeutics’ proposed merger with Houston biopharma firm - Hartford Business Journal
Cara Therapeutics announces merger with Tvardi Therapeutics - Investing.com
Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research - Yahoo Finance
Cara Therapeutics executive Scott Terrillion sells $775 in stock - Investing.com
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire
Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - Investing.com
Cara Therapeutics regains Nasdaq compliance By Investing.com - Investing.com India
Cara Therapeutics regains Nasdaq compliance - Investing.com
Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World
Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal
Cara Therapeutics enacts reverse stock split - Investing.com
Stamford’s Cara Therapeutics to merge with Houston biopharma firm - Hartford Business Journal
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire
STAT3 inhibitors named in Vividion Therapeutics patent - BioWorld MedTech
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):